70 patients diagnosed with ‘migraine without aura’ took part in the study and were given umPEA (600?mg/day orally) for a period of three months. At the end of the study period almost 64 per cent of participants reported a reduction in the severity of their migraines of 50 per cent or more. The number of migraine attacks per month across the study cohort also reduced by more than half.
On average study participants took less than half the painkilling medication for their migraines than they usually would, across the month.
Only one study participant reported mild side effects – nausea and a ‘floating’ sensation.
Researchers who conducted the study acknowledge that the number of people involved was too small for the trial to be definitive however the positive, statistically significant results were very encouraging and warranted a much larger study with a control group.
What is Palmitoylethanolamide?
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide and is found naturally in, and extracted from, food products such as egg, soy, milk and peanuts. It’s also found in healthy human tissue cells but how it functions at a molecular level is still not fully understood and a point of debate amongst medical researchers.
What is known is that side effects are mild and uncommon and it does not interfere with the actions of other drugs. These qualities make it particularly interesting for people suffering with a range of health conditions requiring multiple medications.
Can you get PEA in Australia?
In Australia PEA is classified as a food product and an unscheduled supplement by the Therapeutic Goods Administration. National Custom Compounding can supply PEA to the public without a script, however we recommend people consult with their integrative doctor before starting any new course of treatment. Your doctor will want to review the available information on PEA and consider if it’s the right medication for your particular condition.